USPTO Examiner PACKARD BENJAMIN J - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19011752LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOFJanuary 2025October 2025Allow920NoNo
19011111STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEJanuary 2025November 2025Allow1010NoNo
19005154PHARMACEUTICAL FORMULATIONDecember 2024November 2025Allow1030NoNo
19001318STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEDecember 2024November 2025Allow1010NoNo
18762242PROCESS OF PREPARING MRNA-LOADED LIPID NANO PARTICLESJuly 2024January 2026Allow1820NoNo
18759278COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTIONJune 2024May 2025Allow1110YesNo
18759260COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTIONJune 2024May 2025Allow1110YesNo
18732903Oral Care CompositionsJune 2024November 2025Allow1720NoNo
18674445PHARMACEUTICAL FORMULATIONMay 2024September 2024Allow410NoNo
18651036STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEApril 2024August 2024Allow410NoNo
18651026STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEApril 2024August 2024Allow310NoNo
18625971Functional Porous Particles Embedded/Immobilized Within Porous Structures, Formation & Uses ThereofApril 2024August 2025Abandon1610NoNo
18608182LIPOSOME COMPOSITIONS COMPRISING WEAK ACID DRUGS AND USES THEREOFMarch 2024September 2024Allow610NoNo
18604319Trans-Epithelial Membrane Drug Delivery SystemMarch 2024December 2024Allow910NoNo
18435221RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONSFebruary 2024May 2025Allow1510NoNo
18392891COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATIONDecember 2023June 2025Allow1800NoNo
18526864Transdermal Drug Delivery SystemDecember 2023December 2025Allow2510NoNo
18520172STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USENovember 2023February 2024Allow310NoNo
18504450LIQUID DISPENSING PRODUCT HAVING A SPRAY DISPENSERNovember 2023January 2026Allow2710NoNo
18386863STABLE PARENTERAL FORMULATIONS OF DULOXETINENovember 2023May 2025Allow1830NoNo
18500858HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOFNovember 2023December 2025Abandon2510NoNo
18491953DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATIONOctober 2023November 2025Allow2411NoNo
18491243RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONSOctober 2023November 2024Allow1310NoNo
18554320METHODS OF USING FORMALDEHYDE-FREE ANTIMICROBIAL COMPOSITIONS IN ANIMAL BY-PRODUCT COMPOSITIONSOctober 2023January 2026Allow2810NoNo
18481694COMPOSITIONS FOR TREATING JOINT OR CONNECTIVE TISSUE DISEASE COMPRISING DEXTRAN OR POLOXAMEROctober 2023November 2025Allow2510NoNo
18285550SUBSTRATE FOR DELIVERING A BIOLOGICALLY ACTIVE SUBSTANCEOctober 2023February 2026Allow2800NoNo
18476003Biologically Active Taxane Analogs and Methods of Treatment by Oral AdministrationSeptember 2023July 2025Allow2110NoNo
18371087COMPOSITIONS AND METHODS FOR TREATING DIABETIC FOOT AND OTHER INJURIES AND SORESSeptember 2023May 2025Allow2010YesNo
18367636POLYMER COMPOSITIONSSeptember 2023March 2026Allow3021YesNo
18465226ANTIBIOTIC COMBINATION THERAPIESSeptember 2023April 2025Allow1920NoNo
18281229POLYMERIZABLE 4,4'-SPIROBI[CHROMANE]-2,2'-DIONES AND CURABLE COMPOSITIONS INCLUDING THE SAMESeptember 2023February 2024Allow500NoNo
18461125FAST-ACTING PLANT-BASED MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTSSeptember 2023September 2025Abandon2420NoNo
18241432Cosmetic Material CompositionSeptember 2023April 2025Abandon1910NoNo
18450873Coupling Agent Produced From Naturally Fermented And Sustainable AdditivesAugust 2023December 2024Allow1610NoNo
18447391YEAST-BASED MASKS FOR IMPROVED SKIN, HAIR AND SCALP HEALTHAugust 2023October 2024Allow1410NoNo
18276340COMPOSITIONS AND METHODS FOR TARGETED AMPLIFICATION OF COAGULATION AND PHAGOCYTOSISAugust 2023March 2026Allow3110NoNo
18267953RETRACTION PASTE AND CONTAINER COMPRISING THE RETRACTION PASTEJune 2023August 2025Allow2610NoNo
18332677STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEJune 2023September 2023Allow310NoNo
18331615POROUS CARBON MATERIAL COMPOSITES AND THEIR PRODUCTION PROCESS, ADSORBENTS, COSMETICS, PURIFICATION AGENTS, AND COMPOSITE PHOTOCATALYST MATERIALSJune 2023October 2025Allow2800NoNo
18256563ADHESIVE COMPOSITION FOR HARD TISSUE REPAIRJune 2023January 2026Allow3110NoNo
18206639ANTIMICROBIAL COMPOSITIONJune 2023March 2026Abandon3310NoNo
18255241ORAL FORMULATION COMPRISING 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID AND METHOD FOR PREPARING SAMEMay 2023December 2025Abandon3110NoNo
18201275POLYGLUTAMATED ANTIFOLATES AND USES THEREOFMay 2023August 2024Abandon1510NoNo
18038629PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORSMay 2023October 2025Allow2910NoNo
18318117DRY MIXTURE AND PERSONAL CARE COMPOSITION AS WELL AS METHODS FOR THEIR PRODUCTIONMay 2023May 2025Allow2410NoNo
18313545METHOD FOR MODULATING METABOLISMMay 2023March 2025Allow2220NoNo
18142699CONJUNCTIVAL COVER AND METHODS THEREFORMay 2023May 2024Allow1210NoNo
18250812METHOD FOR THE GRAM-SCALE PREPARATION OF FERRITE NANOPARTICLES FOR MAGNETIC HYPERTHERMIA APPLICATIONSApril 2023January 2026Allow3310NoNo
18307435BROMOCRIPTINE FORMULATIONSApril 2023August 2024Allow1620NoNo
18299658Oral Medicine Delivery CapsuleApril 2023March 2025Allow2330YesNo
18296476Pristine and Ultra-reduced Graphene Oxide as a Carrier for Enzymes and CatalystsApril 2023March 2024Allow1120NoNo
18130490DISSOLVABLE MICRONEEDLES FOR SKIN TREATMENTApril 2023July 2024Abandon1510NoNo
18129969PHARMACEUTICAL FORMULATIONApril 2023November 2023Abandon710NoNo
18247612LIPID NANOPARTICLEMarch 2023June 2025Allow2700NoNo
18124796ORAL CARE COMPOSITIONS FOR PROMOTING GUM HEALTHMarch 2023November 2023Allow810NoNo
18121795METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSESMarch 2023May 2024Allow1410NoNo
18044998SYNTHETIC CYCLIC PEPTIDE MIMETICSMarch 2023January 2026Allow3410NoNo
18182675ORALLY ADMINISTERED COMBINATIONS OF BETA LACTAM ANTIBIOTICS AND AVIBACTAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONSMarch 2023April 2025Abandon2511NoNo
18119251COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTIONMarch 2023November 2023Allow910YesNo
18172843Multi-Targeted Multi-Valent Ligand Drug Particles for the Treatment and Prevention of Diseases and ConditionsFebruary 2023April 2024Abandon1410NoNo
18170704Remote Loading of Sparingly Water-Soluble Drugs Into Lipid VesiclesFebruary 2023April 2024Allow1310NoNo
18018245PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSINJanuary 2023December 2025Allow3501NoNo
18160036METHODS OF TREATING TRIPLE-NEGATIVE BREAST CANCER USING COMPOSITIONS OF ANTIBODIES AND CARRIER PROTEINSJanuary 2023August 2023Allow710NoNo
18085810PHARMACEUTICAL FORMULATIONDecember 2022May 2024Abandon1731NoNo
18067397STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEDecember 2022March 2023Allow310NoNo
18067287STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEDecember 2022March 2023Allow310NoNo
18067605STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USEDecember 2022March 2023Allow310NoNo
18000605FUNGICIDAL COMPOSITIONSDecember 2022September 2025Allow3310NoNo
17928222METHOD FOR DETERMINING OPTIMIZED COMPOSITIONS OF FOOD PRODUCTSNovember 2022January 2026Abandon3701NoNo
18055595Formulations, Methods, and Systems for Treating Genitourinary ConditionsNovember 2022August 2024Allow2120YesNo
18047915IPA-3-LOADED LIPOSOMES AND METHODS OF USE THEREOFOctober 2022January 2024Allow1410NoNo
17959768DENTAL COMPOSITION COMPRISING A PARTICULATE CARRIER SUPPORTING A COINITIATOROctober 2022December 2023Allow1420NoNo
17936184Compounds and Compositions for Ossification and Methods Related TheretoSeptember 2022August 2023Allow1010NoNo
17950979STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USESeptember 2022January 2023Allow410NoNo
17950964STABLE, HIGHLY PURE L-CYSTEINE COMPOSITIONS FOR INJECTION AND METHODS OF USESeptember 2022January 2023Allow410NoNo
17910668AGENT TO BE USED IN INTRAOCULAR MEMBRANE DETACHMENT SURGERYSeptember 2022January 2026Allow4010NoNo
17909697COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONSSeptember 2022December 2025Abandon4001NoNo
17909694COMPOSITIONS AND METHODS FOR THE TREATMENT OF INTRACELLULAR BACTERIAL INFECTIONSSeptember 2022December 2025Abandon4001NoNo
17901688METHOD OF TREATMENT OF TOPICAL DERMATOLOGIC ACNE USING A CREAM COMPOSITION AND METHOD OF MANUFACTURESeptember 2022March 2024Allow1930YesNo
17822872COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATIONAugust 2022September 2023Allow1310NoNo
17887261DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTICS AGENTSAugust 2022November 2023Abandon1501NoNo
17884727Transdermal Drug Delivery SystemAugust 2022August 2023Allow1310NoNo
17816427IONIZABLE LIPID COMPOUNDS, LIPID NANOPARTICLES COMPRISING SAME AND THERAPEUTIC USES THEREOFAugust 2022September 2023Allow1310NoNo
17875724POLYGLUTAMATED ANTIFOLATES AND USES THEREOFJuly 2022May 2023Allow1010NoNo
17813875METHOD FOR MODULATING METABOLISMJuly 2022February 2023Allow711YesNo
17812893BIODEGRADABLE ALPHA-2 AGONIST POLYMERIC IMPLANTS AND THERAPEUTIC USES THEREOFJuly 2022January 2024Abandon1810NoNo
17857302HIGH-EFFICIENCY ENCAPSULATION OF HYDROPHILIC COMPOUNDS IN UNILAMELLAR LIPOSOMESJuly 2022May 2023Allow1110YesNo
17789164COSMETICJune 2022September 2025Abandon3810NoNo
17833326RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONSJune 2022July 2023Allow1310NoNo
17826817RIFABUTIN TREATMENT METHODS, USES, AND COMPOSITIONSMay 2022September 2023Allow1630NoNo
17743056COMPOSITIONS AND METHODS FOR TARGETED DELIVERY OF THERAPEUTICS USING CARRIERSMay 2022November 2025Abandon4201NoNo
17737712PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLESMay 2022April 2024Allow2320NoNo
17772466BACTERIAL BETA-LACTAMASE RESPONSIVE HYDROGELSApril 2022August 2025Allow4010NoNo
17727549DNA-TEMPLATED MICELLE AND USES THEREOFApril 2022December 2025Abandon4410NoNo
17721595ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONSApril 2022May 2025Allow3761YesYes
17707230TREATMENT METHODS FOR MEDICAL AND DENTAL IMPLANTS, PERIODONTAL DISEASES AND MEDICAL PROCEDURESMarch 2022August 2022Allow510NoNo
17703312Combination Therapy for Cancer TreatmentMarch 2022July 2023Allow1610NoNo
17699574YEAST-BASED MASKS FOR IMPROVED SKIN, HAIR AND SCALP HEALTHMarch 2022July 2023Allow1610NoNo
17690862PROGRAMMABLE POLYMERIC DRUGSMarch 2022July 2024Allow2821YesNo
17672676TREATMENT OF CANCERFebruary 2022November 2025Abandon4510NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PACKARD, BENJAMIN J.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
33
Examiner Affirmed
19
(57.6%)
Examiner Reversed
14
(42.4%)
Reversal Percentile
64.9%
Higher than average

What This Means

With a 42.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
133
Allowed After Appeal Filing
31
(23.3%)
Not Allowed After Appeal Filing
102
(76.7%)
Filing Benefit Percentile
31.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 23.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner PACKARD, BENJAMIN J - Prosecution Strategy Guide

Executive Summary

Examiner PACKARD, BENJAMIN J works in Art Unit 1612 and has examined 1,384 patent applications in our dataset. With an allowance rate of 62.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner PACKARD, BENJAMIN J's allowance rate of 62.0% places them in the 22% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by PACKARD, BENJAMIN J receive 1.92 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by PACKARD, BENJAMIN J is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.9% benefit to allowance rate for applications examined by PACKARD, BENJAMIN J. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 37.8% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 60.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 68.3% of appeals filed. This is in the 54% percentile among all examiners. Of these withdrawals, 63.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 45.8% are granted (fully or in part). This grant rate is in the 40% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 2.8% of allowed cases (in the 78% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.